In a milestone for psychedelic healthcare, Oregon has published the first regulations for its psilocybin framework – governing product, testing

Ceruvia Lifesciences focuses on the discovery, development, and delivery of psychedelic medicines to address hard-to-treat disorders such as headache disorders,

On Wednesday, 11 May, thought leaders from across psychedelic healthcare converged at the National Gallery for the inaugural, and sold

The following article was originally published by Psychedelic Alpha. As the psychedelic sector continues to mature, stakeholders from an ever-growing

On 19 April 1943, Albert Hofmann intentionally consumed LSD, marking the first recorded experience with the psychedelic medicine. When Hofmann

More than 280 million people suffer from depression worldwide, with many not responding to conventional treatments, and over 5,000 lives

At the end of 2021, UK-based COMPASS Pathways shared positive results from its Phase IIb clinical trial of COMP360 psilocybin

Acceleration the adoption and accessibility of psychedelic healthcare is crucial to drive innovation in mental health care and improved patient

Novamind today announced it has been contracted by the Usona Institute to provide a research site for its Phase II

It is estimated 15 million people suffer from PTSD each year, with wide-reaching socioeconomic consequences. Many of those afflicted are

Patenting psychedelic medicines, delivery technologies and treatment paradigms provides manufacturers with a period of market exclusivity, incentivising innovation by enabling

PSYCH Symposium: London 2022 will take place at the prestigious National Gallery on Wednesday, 11 May – unlocking the potential